Gan & Lee(SH:603087) 智通财经网·2026-01-21 11:41Core Viewpoint - Gannee Pharmaceutical (603087.SH) expects a significant increase in net profit for the year 2025, projecting a net profit attributable to shareholders of the parent company between 1.1 billion to 1.2 billion yuan, representing an increase of 4.85 billion to 5.85 billion yuan compared to the previous year, which translates to a year-on-year growth of 78.96% to 95.23% [1] Group 1: Domestic Market Performance - The company has leveraged its market coverage advantage gained from centralized procurement to deepen and expand its market presence, resulting in substantial growth in both sales volume and revenue of insulin preparation products [1] Group 2: International Market Strategy - The company is actively advancing its internationalization strategy, achieving significant results in emerging markets along the "Belt and Road" initiative, successfully gaining the trust and cooperation of more international clients, leading to sales growth in several key markets [1] Group 3: Equity Transfer and Profit Increase - In 2025, the company reached an agreement with Guangdong Hengqin Ganling Enterprise Management Co., Ltd. to transfer a total of 70% equity of its wholly-owned subsidiary, Gannee Medical Technology Jiangsu Co., Ltd., in two phases. The first phase has been completed, with 55% of the equity successfully transferred, resulting in increased investment income and contributing to the rise in net profit [1]